Print

First Analysis Of Extended Dosing With Celgene International Sárl (CELG) Epigenetic Agent CC-486 In Patients With Higher-Risk Myelodysplastic Syndromes Presented At American Society of Hematology  
12/9/2013 9:53:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from an ad hoc analysis of a subset of subjects with higher-risk myelodysplastic syndrome (MDS) from two ongoing phase I/II studies of oral epigenetic agent CC-486 (oral azacitidine) were presented at the American Society of Hematology annual meeting in New Orleans, La.

Help employers find you! Check out all the jobs and post your resume.

//-->